<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417688</url>
  </required_header>
  <id_info>
    <org_study_id>201409006</org_study_id>
    <nct_id>NCT02417688</nct_id>
  </id_info>
  <brief_title>PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis</brief_title>
  <official_title>PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With [64]Cu-25%CANF-Comb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate feasibility of imaging Cu[64]-25%-CANF-Comb uptake in the atherosclerosis of&#xD;
      the carotid artery of patients for whom carotid artery endarterectomy surgery is planned in&#xD;
      comparison to the carotid artery for which intervention is not planned.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single center, open-label baseline controlled imaging study designed to&#xD;
      demonstrate feasibility of PET imaging of radiopharmaceutical nanoparticle&#xD;
      Cu[64]-25%CANF-Comb uptake by PET-MR. Patients will undergo Cu[64]-25%CANF-Comb PET-MR&#xD;
      imaging of both carotid arteries. Both carotid arteries will be imaged at the same time. We&#xD;
      hope to demonstrate differences in PET SUV (Standardized Uptake Value) in the significantly&#xD;
      atherosclerotic artery in patients who will be going to carotid endarterectomy surgery in&#xD;
      comparison to the PET SUV in the artery that is not significantly diseased (ie; the artery&#xD;
      that will not undergo surgery) . We also will determine whether PET SUV of the&#xD;
      Cu[64]-25%CANF-Comb by the plaque correlates to the American Heart Association&#xD;
      classifications of atherosclerosis and tissue presence of NPR-C in the ex vivo carotid&#xD;
      endarterectomy specimen post surgery as measured by RT-PCR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET SUV (Standardized Uptake Value)</measure>
    <time_frame>22-26 hours</time_frame>
    <description>Difference in SUV between the carotid with atherosclerosis (carotid artery to be undergo surgery) and the carotid artery without significant disease (artery for which surgery is not planned).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Carotid Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Cu[64]-25%-CANF-Comb PET-MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV injection of 4-8 mCi of Cu[64]-25%-CANF-Comb with a mass no more than 100 Î¼grams followed by PET-MR Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cu[64]-25%-CANF-Comb PET-MR</intervention_name>
    <description>Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR</description>
    <arm_group_label>Cu[64]-25%-CANF-Comb PET-MR</arm_group_label>
    <other_name>Cu[64]-25%-CANF-Comb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with carotid atherosclerosis&#xD;
&#xD;
          -  Patients must be scheduled for carotid intervention (endarterectomy surgery)&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable clinical conditions&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Inability to lie still for up to 60 min with arms down at sides for PET-MR imaging&#xD;
&#xD;
          -  Unwilling to comply with study procedures and unavailable for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Pacemakers, brain aneurysm clip, shrapnel and other typical contraindications for MRI&#xD;
             imaging.&#xD;
&#xD;
          -  Inability to provide written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela K Wooderd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Molly Mohrman</last_name>
    <phone>(314) 747-4633</phone>
    <email>mohrmanm@mir.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Koudelis, RN</last_name>
    <phone>(314) 747-3876</phone>
    <email>koudelisd@mir.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University in St.Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela K Woodard, MD</last_name>
      <phone>314-362-9989</phone>
      <email>woodardp@mir.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela K Woodard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert J Gropler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed A Zayed, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Jim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongjian Liu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liu Y, Pressly ED, Abendschein DR, Hawker CJ, Woodard GE, Woodard PK, Welch MJ. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J Nucl Med. 2011 Dec;52(12):1956-63. doi: 10.2967/jnumed.111.089581. Epub 2011 Nov 2.</citation>
    <PMID>22049461</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Abendschein D, Woodard GE, Rossin R, McCommis K, Zheng J, Welch MJ, Woodard PK. Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET. J Nucl Med. 2010 Jan;51(1):85-91. doi: 10.2967/jnumed.109.066977. Epub 2009 Dec 15.</citation>
    <PMID>20008978</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carotid atherosclerosis, PET imaging agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

